Integrated Investment Consultants LLC Purchases New Holdings in LifeMD, Inc. (NASDAQ:LFMD)

Integrated Investment Consultants LLC acquired a new position in LifeMD, Inc. (NASDAQ:LFMD) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 24,640 shares of the company’s stock, valued at approximately $129,000.

A number of other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of LifeMD by 12.5% in the first quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after purchasing an additional 128,701 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of LifeMD by 261.8% during the 1st quarter. Acadian Asset Management LLC now owns 116,655 shares of the company’s stock worth $1,198,000 after acquiring an additional 84,413 shares during the period. Calamos Advisors LLC bought a new position in shares of LifeMD during the 2nd quarter worth about $394,000. Los Angeles Capital Management LLC boosted its position in shares of LifeMD by 852.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock valued at $637,000 after acquiring an additional 108,822 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in LifeMD in the second quarter valued at about $93,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Stock Performance

NASDAQ:LFMD opened at $5.80 on Friday. The stock has a market capitalization of $251.20 million, a P/E ratio of -9.06 and a beta of 1.23. LifeMD, Inc. has a 1 year low of $3.99 and a 1 year high of $12.88. The firm has a 50 day moving average of $5.03 and a 200-day moving average of $6.19. The company has a current ratio of 0.83, a quick ratio of 0.78 and a debt-to-equity ratio of 10.83.

Analyst Upgrades and Downgrades

LFMD has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price target on shares of LifeMD in a research note on Friday, September 20th. B. Riley assumed coverage on LifeMD in a research note on Friday, August 23rd. They issued a “buy” rating and a $11.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of LifeMD in a research note on Monday, November 11th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, LifeMD has an average rating of “Buy” and an average price target of $12.00.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.